Deep Value: cash covers more than 100% of the stock price

This company holds roughly $79M in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

PMV Pharmaceuticals

PMVP

Biotechnology · Healthcare

Price

$1.33

+0.03 (+2.31%)

Market Cap

$70.9M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+16.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 45.1M (2021) → 52.5M (2025)

Winston Score History

The full picture

PMV Pharmaceuticals is a clinical-stage biotech company focused on developing cancer drugs. Its main focus is a drug called PC14586, which is designed to target a mutated protein called p53 — a protein that is broken or missing in roughly half of all human cancers. The company's potential customers are cancer patients and the hospitals or oncologists who treat them.

PMV makes no product revenue yet because its drugs are still being tested in clinical trials. It is a small U.S.-based company with a market cap around $100 million, funded primarily by cash reserves rather than sales. The company's scientific edge comes from its focus on reactivating mutant p53, an area most drug developers have historically avoided because it was considered too difficult to target. The main risk is that PC14586 could fail in clinical trials, which would severely threaten the company's future since it has no other approved products generating income.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+17.1% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$70M/ year

↑ Rising (+22% vs prior year)

R&D investment increasing — building for the future

Insider Activity

8.3%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~16 months

$79M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-111.1%

Weak — -111.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.00

Conservative — low debt load (0.00)

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial